Compugen Ltd. CGEN
NASDAQ · United States · Health Technology
$2.31-0.03 (-1.28%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced it will host a virtual key opinion leader (KOL) event on Monday, October 5, 2026 at 8:00 AM ET featuring Oladapo Yeku, M.D., Ph.D., FACP (Harvard Medical School, Massachusetts General Hospital), who will join company management to discuss COM701 and the evolving treatment landscape in ovarian cancer. To register, click here.
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, being held from September 14-16 in New York City.
Compugen Ltd (CGEN) reports solid cash position and progress in its MyOvarian trial, despite revised placebo assumptions and a distant timeline for key partnership milestones.
Moby summary of Compugen Ltd.'s Q2 2026 earnings call
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today reported financial results for the second quarter of 2026 and provided a corporate update.
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the BTIG Biotechnology Conference 2026 taking place virtually from July 28-29, 2026.
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its second quarter 2026 financial results on Monday, August 3, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, in Copenhagen, Denmark.
Compugen’s analyst story has shifted, with one research firm cutting its price target from US$13 to US$5 while another framework holds a fair value estimate at US$4.6. That split echoes the latest commentary, where bullish analysts keep positive ratings but more cautious voices point to tighter assumptions and a reduced upside case. As you read on, you will see how to track these changing signals and what they might mean for following the evolving Compugen narrative over time. Stay updated as...
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, taking place from June 17 to June 19, 2026, in Copenhagen, Denmark.
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will participate in Jones Trading's Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ ML-based Drug Development on Monday, June 15, 2026, from 10:30-11:00 AM ET.
The recent cut in Compugen’s price target from US$13 to US$5, alongside a fair value reset from US$6.25 to US$4.60, marks a clear shift in how the stock is being valued. Some analysts still see room between the current share price and the revised US$5 target, while others are using the lower levels to reflect tighter assumptions and higher perceived risk. As you read on, you will see what is driving this split view and how to track the evolving story around Compugen. Wall Street's queuing for...
Compugen Ltd (CGEN) showcases promising clinical progress and a strong cash position, despite facing revenue and net loss hurdles in Q1 2026.
Moby summary of Compugen Ltd.'s Q1 2026 earnings call
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.